How The Pfizer/Allegan Deal Got Done: Inside The Twists And Turns Of A Mega-Merger
The deal to combine Pfizer and Allergan was the culmination of 16 months of negotiations, beginning with a dinner between Ian Read and Brent Saunders in July 2014, well before the company that was then Actavis had even disclosed its interest in merging with Allergan.
You may also be interested in...
Treasury announced new regulations aimed at blocking tax-motivated deals, leaving the largest mega-deal in the history of pharma hanging in the balance.
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.